Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: Study protocol for a systematic review and network meta-analysis

BMJ Open

Volumn 5, Issue 9, 2015, Pages

  Zhou, Xinyu ^a   Qin, Bin ^a   Whittington, Craig ^b   Cohen, David ^c   Liu, Yiyun ^a   Del Giovane, Cinzia ^d   Michael, Kurt D ^e   Zhang, Yuqing ^a   Xie, Peng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e APPALACHIAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ADVERSE OUTCOME; BIBLIOGRAPHIC DATABASE; CHILD PSYCHIATRY; CINAHL; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; DATA EXTRACTION; DEPRESSION; DEPRESSION ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; HUMAN; LILACS DATABASE; MEDLINE; META ANALYSIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUICIDE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEB OF SCIENCE; ADOLESCENT; CHILD; DEPRESSIVE DISORDER; DRUG TOLERANCE; PSYCHOLOGICAL RATING SCALE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER; DRUG TOLERANCE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84947936788     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007768     Document Type: Review

References (49)

1. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547.
2. Ryan ND. Treatment of depression in children and adolescents. Lancet 2005;366:933-40.
3. Rao U, Ryan ND, Birmaher B, et al. Unipolar depression in adolescents: clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry 1995;34:566-78.
4. Jaffee SR, Moffitt TE, Caspi A, et al. Differences in early childhood risk factors for juvenile-onset and adult-onset depression. Arch Gen Psychiatry 2002;59:215-22.
5. Office of the Surgeon General. The Surgeon Generals call to action to prevent suicide. Washington DC: Department of Health and Human Services, 1999.
6. Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years-United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007;56:905-8.
7. Pfeffer CR. Suicide among youth: perspectives on risk and prevention. Washington DC: American Psychiatric Press, 1989: 203-25.
8. Lieberman JAI. History of the use of antidepressants in primary care. J Clin Psychiatry 2003;5:6-10.
9. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17-25.
10. Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2013;6:CD002317.
11. Biederman J. Sudden death in children treated with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatry 1991;30:495-8.
12. Varley CK, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997;36:390-4.
13. Green WH. Child and Adolescent clinical psychopharmacology. 3rd edn. Philadelphia: Lippincott Williams and Wilkins, 2003:169-72.
14. Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012;11:CD004851.
15. Bennett K, Teeling M, Feely J. Overprescribing antidepressants to children: pharmacoepidemiological study in primary care. BMJ 2005;331:1451-2.
16. Fegert JM, Klch M, Zito JM, et al. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 2006;16:197-206.
17. Gentile S. Antidepressant use in children and adolescents diagnosed with major depressive disorder: what can we learn from published data? Rev Recent Clin Trials 2010;5:63-75.
18. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72:71-9.
19. U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. http:// www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformation forpatientsandproviders/ucm161679.htm (accessed 11 Dec 2014).
20. Adverse Drug Reactions Advisory Committee. Use of SSRI antidepressants in children and adolescents. https://www.tga.gov.au/ use-ssri-Antidepressants-children-And-Adolescents-june-2004 (accessed 1 Dec 2014).
21. Canadian Psychiatric Association Bulletin. Health Canada to examine SSRIs in children, April 2004. http://ww1.cpa-Apc.org/ Publications/Archives/Bulletin/2004/april/news32En.asp (accessed 18 Dec 2014).
22. National Institute of Mental Health. Antidepressant medications for children and adolescents: information for parents and caregivers. http://www.nimh.nih.gov/health/topics/child-And-Adolescent-mentalhealth/ antidepressant-medications-for-children-And-Adolescentsinformation-for-parents-And-caregivers.shtml (accessed 14 Dec 2014).
23. Papanikolaou K, Richardson C, Pehlivanidis A, et al. Efficacy of antidepressants in child and adolescent depression: a meta-Analytic study. J Neural Transm 2006;113:399-415.
24. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363: 1341-5.
25. Qin B, Zhang Y, Zhou X, et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-Analysis of efficacy and acceptability. Clin Ther 2014;36: 1087-95.
26. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
27. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
28. Zhou X, Ravindran A, Qin B, et al. Comparative efficacy, acceptability and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-Analysis. J Clin Psychiatry 2015;76:e487-98.
29. Qin B, Zhou X, Michael KD, et al. Psychotherapy for depression in children and adolescents: study protocol for a systematic review and network meta-Analysis. BMJ Open 2015;5:e005918.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edn. Washington DC: American Psychiatric Association, 1980.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edn. Washington DC: American Psychiatric Association, 1987.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington DC: American Psychiatric Association, 1994.
33. World Health Organization (WHO). The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organization, 1978.
34. World Health Organization (WHO). The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization, 1992.
35. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-Dreatments meta-Analysis. Lancet 2009;373:746-58.
36. Poznanski EO, Mokros HB. Childrens depression rating scale, revised (CDRS-R): manual. Los Angeles, CA: Western Psychological Services, 1996.
37. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
38. Brooks SJ, Kutcher S. Diagnosis and measurement of depression: a review of commonly utilized instruments. J Child Adolesc Psychopharmacol 2001;11:341-76.
39. Beck AT, Steer R. Beck depression inventory: manual. San Antonio, TX: Psychological Corporation, 1987.
40. Kovacs M. The Childrens Depression, Inventory (CDI). Psychopharmacol Bull 1985;21:995-8.
41. Riedel M, Mller HJ, Obermeier M, et al. Response and remission criteria in major depression-A validation of current practice. J Psychiatr Res 2010;44:1063-8.
42. Hammad TA. Review and evaluation of clinical data. Washington DC: US Food and Drug Administration. http://www.fda.gov/ohrms/ dockets/ac/04/briefing/2004-4065b1-10-Dab08-hammads-review.pdf (accessed 9 Dec 2014).
43. Reynolds WM. Suicidal ideation questionnaire-junior. Odessa, FL: Psychological Assessment Resources, 1987.
44. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration, 2011.
45. Follmann D, Elliott P, Suh I, et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992;45:769-73.
46. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55.
47. Lu GB, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;101:447-59.
48. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-Dreatment metaanalysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
49. Dias S, Sutton AJ, Welton NJ, et al. Evidence synthesis for decision making 3: heterogeneity-subgroups, meta-regression, bias, and bias-Adjustment. Med Decis Making 2013;33:618-40.